McCormick and DeLauro Introduce CLEAR LABELS Act to Track Drug Ingredients
The CLEAR LABELS Act is in the early stages of the legislative process and is currently sitting in two House committees. Since April 13, 2026, the bill has not moved forward, and it must receive a vote from these committees before it can proceed. Most bills do not move past this stage, and there are no upcoming actions scheduled for this proposal.
The bill has support from both parties, which helps its chances. However, many bills like this struggle to get a full vote in the House and Senate before the session ends.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Small pharmaceutical companies, independent pharmacies that repackage drugs, and small distributors would face new compliance costs to update labeling, create electronic portals, and track supply chain information. While the bill allows QR codes and electronic alternatives that reduce physical labeling burden, the administrative effort to identify and verify original manufacturers could be costly for smaller players.
“A manufacturer, packer, or distributor required to furnish information under subparagraphs (1), (2), and (3), in addition to making such information available electronically, as applicable, shall make such information available through a package insert, or in paper copy to any individual who requests such a copy.”
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Representatives Rich McCormick and Rosa DeLauro introduced the bipartisan CLEAR LABELS Act in the House. The bill requires drug labels to list original manufacturers of both drugs and active ingredients, allowing for digital formats like QR codes while ensuring consumer transparency.
The CLEAR LABELS Act proposes requiring drug companies to disclose manufacturing locations for generic drugs and APIs. The bill suggests using QR codes on packaging to link to a searchable database with manufacturing details and drug quality scores.
Sen. Katie Britt joined colleagues in introducing the CLEAR LABELS Act, which would require drug labels to disclose original manufacturers. The bill aims to provide patients and providers with clear information about where their medications are produced.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
CLEAR LABELS Act
Analysis generated by AI. Always verify with official sources.